CGC — Canopy Growth Corporation

Summary of Canopy Growth's Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: Q2 cannabis net revenue was CAD 51 million, a 12% increase year-over-year, driven by a 30% increase in the Canadian adult-use segment and a 17% increase in the medical segment.
• Adjusted EBITDA: Loss narrowed to CAD 3 million from CAD 6 million a year ago, reflecting improved margins and lower SG&A expenses.
• Cash Position: As of September 30, 2025, Canopy had CAD 298 million in cash, exceeding debt by CAD 70 million. The company prepaid USD 50 million on its term loan, saving approximately USD 6.5 million in annual interest.
• Gross Margin: Cannabis gross margin was 31%, down year-over-year but up from 24% in Q1 2026.

2. Strategic Updates and Business Highlights

• Canadian Adult-Use Growth: Strong demand for Claybourne infused pre-rolls and new Tweed All-In-One vapes contributed to revenue growth. Distribution increased by 20% among Alberta independent retailers.
• Medical Cannabis Strategy: Continued focus on patient experience with a 20% increase in insured patient registrations year-over-year.
• Storz & Bickel Performance: Revenue from this segment was CAD 16 million, up 5% sequentially, driven by the new VEAZY vaporizer.
• Cost Management: SG&A expenses decreased by 13% year-over-year, with a total of CAD 21 million in annualized savings achieved from cost-saving initiatives.

3. Forward Guidance and Outlook

• Canadian Market: Expected continued growth in both adult-use and medical cannabis segments for the remainder of fiscal 2026, supported by a robust innovation pipeline.
• International Markets: Anticipated stabilization and improvement in European operations, with growth expected as the fiscal year progresses.
• Storz & Bickel: Expected stronger performance driven by holiday season sales and the successful launch of the VEAZY vaporizer.
• Profitability Goals: The company aims for positive adjusted EBITDA, focusing on cost savings and operational efficiencies.

4. Challenges and Points of Concern

• International Market Performance: Q2 saw a CAD 3 million decline in international revenues, primarily due to supply constraints and quality issues in Europe.
• Government Proposals: Proposed changes to medical cannabis reimbursement for veterans could impact access and quality of care, raising concerns about potential revenue implications.
• Economic Pressures: Ongoing economic uncertainty, particularly in the U.S., may affect consumer sentiment and profitability for Storz & Bickel.

5. Notable Q&A Insights

• Supply Chain Issues: Management acknowledged challenges in European supply chains but expressed confidence in resolving these issues without significant cost increases.
• Capital Allocation: The company is evaluating capital requirements and funding strategies, with no immediate plans for significant new investments.
• U.S. Operations: Canopy USA operates independently, with no financial guarantees from Canopy Growth, and is focused on execution and integrating its operations.

Overall, Canopy Growth reported a strong Q2 with significant revenue growth in its Canadian markets, improved financial metrics, and a commitment to addressing challenges in international operations. The company remains focused on achieving profitability while navigating potential regulatory impacts and economic uncertainties.